DSS (DSS) Q3 2025 earnings summary

Executive summary

• Revenue for the nine months ended September 30, 2025 increased 22% year-over-year to $16.6 million, driven by growth in printed products and securities rental income.

• Net loss narrowed to $10.1 million from $15.8 million in the prior year period, reflecting higher revenues and investment gains.

• The company operates five business lines: Product Packaging, Biotechnology, Commercial Lending, Securities & Investment Management, and Direct Marketing.

Financial highlights

• Printed products revenue rose 16% year-over-year to $13.2 million for the nine months, with new and existing customer orders exceeding forecasts.

• Securities revenue (rental and commission) increased 61% to $3.3 million, mainly from new tenants at medical real estate facilities.

• Net investment income declined 80% due to loans on non-accrual status.

• Total costs and expenses decreased 3% year-over-year, with cost of revenue down 3% and SG&A up 21% due to a bonus payment.

• Gain on investments of $1.1 million and a $595,000 gain on extinguishment of debt contributed to improved results.

Outlook and guidance

• Management believes it has sufficient cash and access to capital to meet requirements for at least the next 12 months.

• The company is focused on expense reduction and cash burn control at all levels.